Trial Profile

A First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of anle138b in Healthy Male and Female Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emrusolmin (Primary)
Indications Multiple system atrophy
Focus Adverse reactions; First in man
Sponsors Modag

Most Recent Events

05 Aug 2020 According to Modag media release, based on the positive Phase 1 study results, MODAG was also able to obtain additional funding of USD 1.4 million from The Michael J. Fox Foundation for Parkinson's Research.
05 Aug 2020 Status changed from active, no longer recruiting to completed.
04 Aug 2020 Planned primary completion date changed from 1 Aug 2020 to 3 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com